HK1088893A1 - Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives - Google Patents

Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives

Info

Publication number
HK1088893A1
HK1088893A1 HK06108282A HK06108282A HK1088893A1 HK 1088893 A1 HK1088893 A1 HK 1088893A1 HK 06108282 A HK06108282 A HK 06108282A HK 06108282 A HK06108282 A HK 06108282A HK 1088893 A1 HK1088893 A1 HK 1088893A1
Authority
HK
Hong Kong
Prior art keywords
pyrimidin
perfluoroalkyl
derivatives
substituted
Prior art date
Application number
HK06108282A
Other languages
English (en)
Inventor
Lochead Alistair
Saady Mourad
Slowinski Franck
Yaiche Phillipe
Original Assignee
Sanofi Aventis
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis, Mitsubishi Pharma Corp filed Critical Sanofi Aventis
Publication of HK1088893A1 publication Critical patent/HK1088893A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK06108282A 2003-03-21 2006-07-25 Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives HK1088893A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03290728A EP1460076A1 (en) 2003-03-21 2003-03-21 Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
PCT/EP2004/004013 WO2004083210A1 (en) 2003-03-21 2004-03-19 SUBSTITUTED 8-PERFLUOROALKYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES

Publications (1)

Publication Number Publication Date
HK1088893A1 true HK1088893A1 (en) 2006-11-17

Family

ID=32799141

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06108282A HK1088893A1 (en) 2003-03-21 2006-07-25 Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives

Country Status (26)

Country Link
US (2) US7217715B2 (xx)
EP (2) EP1460076A1 (xx)
JP (1) JP4572194B2 (xx)
KR (1) KR101070075B1 (xx)
CN (1) CN100368412C (xx)
AR (1) AR053082A1 (xx)
AT (1) ATE433977T1 (xx)
AU (1) AU2004222105B2 (xx)
BR (1) BRPI0408605A (xx)
CA (1) CA2517774C (xx)
CY (1) CY1109345T1 (xx)
DE (1) DE602004021572D1 (xx)
DK (1) DK1608653T3 (xx)
EA (1) EA009198B1 (xx)
ES (1) ES2328812T3 (xx)
HK (1) HK1088893A1 (xx)
IL (1) IL170634A (xx)
MX (1) MXPA05010112A (xx)
NO (1) NO20054331L (xx)
NZ (1) NZ542224A (xx)
PL (1) PL1608653T3 (xx)
PT (1) PT1608653E (xx)
SI (1) SI1608653T1 (xx)
TW (1) TWI322809B (xx)
WO (1) WO2004083210A1 (xx)
ZA (1) ZA200507192B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1460076A1 (en) * 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
JP4277826B2 (ja) 2005-06-23 2009-06-10 住友電気工業株式会社 窒化物結晶、窒化物結晶基板、エピ層付窒化物結晶基板、ならびに半導体デバイスおよびその製造方法
US8771552B2 (en) * 2005-06-23 2014-07-08 Sumitomo Electric Industries, Ltd. Group III nitride crystal substrate, epilayer-containing group III nitride crystal substrate, semiconductor device and method of manufacturing the same
US9708735B2 (en) 2005-06-23 2017-07-18 Sumitomo Electric Industries, Ltd. Group III nitride crystal substrate, epilayer-containing group III nitride crystal substrate, semiconductor device and method of manufacturing the same
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1790649A1 (en) * 2005-11-21 2007-05-30 Sanofi-Aventis Substituted bicyclic pyrimidone derivatives
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP1939187A1 (en) * 2006-12-20 2008-07-02 Sanofi-Aventis Substituted heteroaryl pyridopyrimidone derivatives
EP2138493A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
EP2138495A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
EP2138498A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted tricyclic derivatives against neurodegenerative diseases
EP2138488A1 (en) 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
EP2138485A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted N-Oxide pyrazine derivatives
EP2138494A1 (en) * 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
EP2138492A1 (en) * 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidin-4-one derivatives
JP5655070B2 (ja) 2009-07-02 2015-01-14 サノフイ 新規６，７，８，９−テトラヒドロピリミド｛１，２−ａ｝ピリミジン−４−オン誘導体、これらの調製およびこれらの医薬的使用
PL2655375T3 (pl) 2010-12-23 2015-05-29 Sanofi Sa Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
FR2992316A1 (fr) 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
JP2001270884A (ja) * 2000-03-23 2001-10-02 Mitsubishi-Tokyo Pharmaceuticals Inc ピリミドン誘導体
WO2002018386A1 (en) * 2000-09-01 2002-03-07 Sanofi-Synthelabo 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a]PYRIMIDIN-5(1H)ONE DERIVATI VES
EP1184383A1 (en) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives
EP1460076A1 (en) * 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives

Also Published As

Publication number Publication date
CA2517774C (en) 2011-10-18
PL1608653T3 (pl) 2009-12-31
US7393853B2 (en) 2008-07-01
DK1608653T3 (da) 2009-10-05
JP2006520766A (ja) 2006-09-14
ZA200507192B (en) 2007-03-28
ATE433977T1 (de) 2009-07-15
CN1784407A (zh) 2006-06-07
TW200505922A (en) 2005-02-16
NO20054331D0 (no) 2005-09-20
NZ542224A (en) 2008-11-28
ES2328812T3 (es) 2009-11-18
CN100368412C (zh) 2008-02-13
PT1608653E (pt) 2009-09-07
TWI322809B (en) 2010-04-01
US20060035910A1 (en) 2006-02-16
EA009198B1 (ru) 2007-12-28
CY1109345T1 (el) 2014-07-02
WO2004083210A1 (en) 2004-09-30
MXPA05010112A (es) 2006-05-17
KR20050111781A (ko) 2005-11-28
AU2004222105B2 (en) 2010-03-04
EP1608653B1 (en) 2009-06-17
EP1608653A1 (en) 2005-12-28
EA200501311A1 (ru) 2006-04-28
AR053082A1 (es) 2007-04-25
US7217715B2 (en) 2007-05-15
EP1460076A1 (en) 2004-09-22
KR101070075B1 (ko) 2011-10-04
AU2004222105A1 (en) 2004-09-30
US20070191384A1 (en) 2007-08-16
JP4572194B2 (ja) 2010-10-27
BRPI0408605A (pt) 2006-03-07
NO20054331L (no) 2005-12-21
CA2517774A1 (en) 2004-09-30
DE602004021572D1 (de) 2009-07-30
IL170634A (en) 2012-02-29
SI1608653T1 (sl) 2009-12-31

Similar Documents

Publication Publication Date Title
HK1088893A1 (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives
HK1086012A1 (en) 8-substitued-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives
HK1090368A1 (en) 2,3,6-trisubstituted-4-pyrimidone derivatives
SI1699795T1 (sl) Substituirani 8-piri(mi)dinil-dihidrospiro-(cikloalkilamin)pirimido(1,2a) pirimidin-6-onski derivati
HK1093503A1 (en) Pyrido 2, 1-a-isoquinoline derivatives as ddp-IV inhibitors
ZA200606974B (en) Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
AP2005003198A0 (en) Spiroindolinepiperidine derivatives.
ZA200500170B (en) Indole-3-sulphur derivatives.
AP2005003343A0 (en) Substituted pyrrolo-pyrazole derivatives as kinaseinhibitors
HK1088602A1 (en) 2-pyridinecarboxamide derivatives
HK1088326A1 (en) Piperidine-benzenesulfonamide derivatives
HK1089443A1 (en) Imidazol-4-yl-ethynyl-pyridine derivatives
GB0317665D0 (en) Qinazoline derivatives
SI1682493T1 (sl) Amidoacetonitrilni derivati
ZA200506744B (en) PyrazoloÄ1,5-AÜpyrimidine derivatives
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
SI1706373T1 (sl) Amidoacetonitrilni derivati
GB0312368D0 (en) Novel ureido- and amido-pyrazolone derivatives
GB0319793D0 (en) Pyridinylmorpholine derivatives
ZA200505352B (en) Novel substituted 2,3-benzodiazepine derivatives
EP1711189A4 (en) AZALIDE DERIVATIVES 8A 6,11-3C-BICYCLIC
SI1549647T1 (sl) Substituirani C-imidazo(1,2-a)piridin-3-il-metilamini
TWI341309B (en) Heteroarylcarbamoylbenzene derivatives
SI1654253T1 (sl) Substituirani 3-pirolidin-indolni derivati
GB0216664D0 (en) 1,4-Dihydro-1,4-diphenylpyridine derivatives

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130319